biostudies-literatureSalem RNCRR NIH HHSNCI NIH HHS497-507.e2https://www.ebi.ac.uk/biostudies/studies/S-EPMC3129335biostudies-literatureUnknown140(2)<h4>Background & aims</h4>Chemoembolization is one of several standards of care treatment for hepatocellular carcinoma (HCC). Radioembolization with Yttrium-90 microspheres is a novel, transarterial approach to radiation therapy. We performed a comparative effectiveness analysis of these therapies in patients with HCC.<h4>Methods</h4>We collected data from 463 patients who were treated with transarterial locoregional therapies (chemoembolization or radioembolization) over a 9-year period. We excluded patients who were not appropriate for comparison and analyzed data from 245 (122 who received chemoembolization and 123 who received radioembolization). Patients were followed for signs of toxicity; all underwent imaging analysis at baseline and follow-up time points. Overall survival was the GastroenterologyRadioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.PMC3129335R01 CA126809-04CA126809R01 CA126809-02R01 CA126809-03R01 CA126809R01 CA126809-01A2UL1 RR025741Sato KTResnick SAIbrahim SMYaghmai VWang EGates VLCarr JChrisman HBKulik LNikolaidis PRiaz ASalem RMulcahy MFVogelzang RLAbecassis MChen RLewandowski RJGupta RNewman SRyu RKNemcek AAOmary RABenson ABAtassi BMemon KSenthilnathan SMiller FHBaker TfalseRadioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.<h4>Background & aims</h4>Chemoembolization is one of several standards of care treatment for hepatocellular carcinoma (HCC). Radioembolization with Yttrium-90 microspheres is a novel, transarterial approach to radiation therapy. We performed a comparative effectiveness analysis of these therapies in patients with HCC.<h4>Methods</h4>We collected data from 463 patients who were treated with transarterial locoregional therapies (chemoembolization or radioembolization) over a 9-year period. We excluded patients who were not appropriate for comparison and analyzed data from 245 (122 who received chemoembolization and 123 who received radioembolization). Patients were followed for signs of toxicity; all underwent imaging analysis at baseline and follow-up time points. Overall survival was the 2011-01-01T00:00:00Z2011 Feb2025-04-21T20:40:41.699Z2019-03-27T03:06:40ZS-EPMC31293352104463010.1053/j.gastro.2010.10.049